Skip to content
OpenCapital
Get started

Organon OGN Other Biosimilars — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXBiosimilar — Net revenue
$22.3M-21.9%
Biogen logo
BIIBBiosimilars — Total Revenue
$182.2M+0.8%
Veracyte logo
VCYTBiopharmaceutical and other revenue — Total Revenue
$301K-91.6%
Vertex Pharmaceuticals logo
VRTXOther revenues — Product revenues, net
$0-100%
Regeneron Pharmaceuticals logo
REGNOther products — Revenue
$31.3M—
Veracyte logo
VCYTBiopharmaceutical revenue — Total Revenue
$301K-86.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's other biosimilars — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's other biosimilars — revenue?
Organon (OGN) reported other biosimilars — revenue of $24M in Q1 2026.
How has Organon's other biosimilars — revenue changed year-over-year?
Organon's other biosimilars — revenue increased by 380.0% year-over-year, from $5M to $24M.
What is the long-term trend for Organon's other biosimilars — revenue?
Over 2 years (2021 to 2025), Organon's other biosimilars — revenue has grown at a -19.6% compound annual growth rate (CAGR), from $51M to $33M.
What does other biosimilars — revenue mean?
This metric represents the total net sales generated from the company's portfolio of biosimilar products categorized outside of its primary therapeutic focus areas. It reflects the market demand and commercial performance of secondary biosimilar assets within the broader pharmaceutical segment. Tracking this revenue stream helps investors evaluate the contribution of niche or non-core biosimilar offerings to the company's overall top-line growth.